Orchard Therapeutics plc - ADR

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.

Orchard Therapeutics plc (NASDAQ:ORTX ) Q4 2022 Earnings Conference Call March 6, 2023 8:00 AM ET Company Participants Bobby Gaspar - Chief Executive Officer Frank Thomas - President and COO Braden Parker - Chief Commercial Officer Leslie Meltzer - Chief Medical Officer Conference Call Participants Dae Gon Ha - Stifel Hartaj Singh - Oppenheimer Brendan Smith - TD Cowen David Hoang - SMBC Nikko Securities Robert Finke - Guggenheim Securities Pete Stavropoulos - Cantor Fitzgerald Bobby Gaspar Hello, everyone. I'm Bobby Gaspar, CEO and Co-Founder of Orchard.

Orchard Therapeutics plc (ORTX) Q4 2022 Earnings Call Transcript

BOSTON and LONDON, March 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Company's previously disclosed change to its American Depositary Share ("ADS") to ordinary share ratio has been made effective. The ratio has changed from one ADS to one ordinary share to the new ratio of one ADS to ten ordinary shares.

Orchard Therapeutics Completes ADS Ratio Change

OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA)

Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results

Proceeds to accelerate commercialization of Libmeldy and advance the company's HSC gene therapy R&D portfolio

Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million

BOSTON and LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor conferences:

Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023

BOSTON and LONDON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with the New Therapies (NT) Council which will result in reimbursed access to Libmeldy® (atidarsagene autotemcel) for all metachromatic leukodystrophy (MLD) patients who fall within the scope of the European marketing authorization in Sweden. Libmeldy received the strongest possible recommendation for use by the NT Council following the completion of a health economic evaluation by FINOSE, a health technology assessment consortium between Finland, Norway and Sweden.

Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden

Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years of follow-up (median 6.15 years)

Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™

BOSTON and LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value £0.10 per share, from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to ten (10) ordinary shares (the “ADS Ratio Change”). The Company anticipates that the ADS Ratio Change will be effective on or about March 10, 2023 ( the “Effective Date”).

Orchard Therapeutics Announces Proposed ADS Ratio Change

Four oral presentations and 11 posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases Four oral presentations and 11 posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases

Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium

Libmeldy® revenue totaled $5.8M in Q4 2022 and $18.8M for the full year with commercial expansion activities continuing in Europe

Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones

ABVC BioPharma

Akili Inc

Bellerophon Therapeutics

Eloxx Pharmaceuticals Inc

Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Penny Stocks Exploding After News This Week

Global registrational trial expected to commence in the second half of 2023 Global registrational trial expected to commence in the second half of 2023

Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

Orchard Therapeutics is one of these tickers that, after losing approximately 65% of its value over the past twelve months, has a market cap of around $55M. ORTX has a price-to-book of 0.45 and an enterprise value of about -$32M. What is more, ORTX has a price-to-sales of 2.72x.

Orchard Therapeutics: Growing A Position In This Undervalued Gene Therapy Play

All patients achieved sustained engraftment and supraphysiological SGSH enzyme levels with median 1.5 years follow-up

Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA

BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced its marketing authorization application (MAA) for Libmeldy® (atidarsagene autotemcel) has been accepted for evaluation by the Swiss Agency for Therapeutic Products (Swissmedic) for the potential treatment of eligible patients with early-onset metachromatic leukodystrophy (MLD). The Swiss filing was based on the European Union (EU) MAA for Libmeldy, which was approved by the European Commission in December 2020. Libmeldy is registered in the EU, Iceland, Liechtenstein, Norway and the United Kingdom (UK). The company expects to receive Swissmedic's assessment report in the first half of 2023.

Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel)

Orchard Therapeutics plc (NASDAQ:ORTX ) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Bobby Gaspar - Chief Executive Officer Braden Parker - Chief Commercial Officer Frank Thomas - President and COO Leslie Meltzer - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald David Hoang - SMBC Group Operator Thank you for standing by. My name is Rihanna and I will be your conference operator today.

Orchard Therapeutics plc (ORTX) Q3 2022 Earnings Call Transcript

Libmeldy ® product sales totaled $4.8M in Q3 and $13.0M YTD with market expansion activities continuing in Europe

Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights

BOSTON and LONDON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following investor conferences:

Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022

BOSTON and LONDON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Monday, November 14, 2022, at 8:00 a.m. EST to review business updates and its third quarter 2022 financial results.

Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results

Company to host KOL conference call and webcast on Monday, December 12 at 5:00 p.m. EST Company to host KOL conference call and webcast on Monday, December 12 at 5:00 p.m. EST

Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022

Clinical and pre-clinical data from across the company's portfolio will be featured in four oral and six poster presentations

Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas

BOSTON and LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced seven presentations from across its neurometabolic portfolio will be featured at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place from August 30 to September 2, 2022, in Freiburg, Germany.

Orchard Therapeutics Announces Multiple Presentations at 2022 SSIEM Annual Symposium Highlighting Neurometabolic Disease Portfolio

Additional Libmeldy ® reimbursement discussions advancing across Europe with product sales totaling $3.1M in Q2 and $8.2M YTD

Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights

Orchard Therapeutics PLC (NASDAQ:ORTX ) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Bobby Gaspar - CEO Braden Parker - Chief Commercial Officer Frank Thomas - President & COO Leslie Meltzer - Chief Medical Officer Conference Call Participants Brendan Smith - Cowen and Company Dae Gon Ha - Stifel, Nicolaus & Company Pete Stavropoulos - Cantor Fitzgerald & Co. David Hoang - SMBC Tessa Romero - JPMorgan Chase & Co/ Operator Welcome to the Orchard Therapeutics Q1 2022 Earnings Conference Call. My name is John.

Orchard Therapeutics PLC (ORTX) CEO Bobby Gaspar on Q1 2022 Results - Earnings Call Transcript

Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022

News for Orchard Therapeutics plc - ADR Stock (ORTX)